SparingVision to Highlight Progress of its Lead Gene Therapy Program SPVN06 and Research on Retinitis Pigmentosa at ARVO 2023

SparingVision to Highlight Progress of its Lead Gene Therapy Program SPVN06 and Research on Retinitis Pigmentosa at ARVO 2023 Paris, April 11, 2023 – SparingVision (“the Company”), a clinical-stage genomic medicine company developing vision-saving treatments for ocular diseases, today announces announces today that it has been selected for three poster presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting to be held from 23-27 April. Poster Presentation: Nonclinical safety and pharmacokinetic assessment of SPVN06, an AAV-based gene therapy for the treatment of rod-cone dystrophies Date and Time: 23 April, 12:00 – 2:00 PM, Poster #773 – C0374 Presenter: Anne-Sophie Gautron, PhD Session Title: Gene therapy and gene editing for ocular disorders Session Number: 140 Poster Presentation: Mouse model selection for pharmacological evaluation of AAV-based therapeutic agents for the treatment of rod-cone dystrophies (RCD) Date and Time: 25 April, 8:45 AM – 10:45 AM, Poster #2591 – B0304 Presenter: Melanie Marie, PhD Session Title: Retina/RPE: New drugs, mechanisms of action and toxicity Session Number: 320 Poster Presentation: Mobility and postural testing in patients with rod-cone dystrophy enrolled in the prospective natural history study PHENOROD2 Date and Time: 26 April, 2:15 – 4:15 PM, Poster #4644 – C0109 Presenter: Mylène Poujade Session Title: Retinitis pigmentosa Session Number: 450 **ENDS**

The release as fetched from its publisher. sparingvision.com ↗